Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
491.49
+4.17 (+0.86%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
↗
August 26, 2025
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.
Via
Benzinga
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
August 26, 2025
Via
Benzinga
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
August 20, 2025
In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
↗
August 18, 2025
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.
Via
Investor's Business Daily
Earnings Scheduled For August 5, 2025
↗
August 05, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
Why Madrigal Pharmaceuticals Stock Is Soaring Today
↗
February 26, 2025
Via
The Motley Fool
Earnings Scheduled For February 26, 2025
↗
February 26, 2025
Via
Benzinga
Why Madrigal Pharmaceuticals Stock Is Sinking Today
↗
January 13, 2025
Via
The Motley Fool
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
↗
August 18, 2025
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Via
Benzinga
Billionaire Investor Buys Google And This Gold Miner Stock
↗
August 16, 2025
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Via
Benzinga
Madrigal (MDGL) Q2 Revenue Soars 1,313%
↗
August 05, 2025
Via
The Motley Fool
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales
↗
August 05, 2025
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.
Via
Chartmill
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
↗
June 20, 2025
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
Via
Benzinga
5 Health Care Stocks With Whale Alerts In Today's Session
↗
June 20, 2025
Via
Benzinga
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
↗
May 13, 2025
Via
The Motley Fool
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
↗
May 11, 2025
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,...
Via
Stocktwits
Topics
Death
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
↗
April 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 25, 2025
Via
Benzinga
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday
↗
February 26, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
February 26, 2025
Via
Benzinga
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
↗
February 26, 2025
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.
Via
Benzinga
8 Health Care Stocks Whale Activity In Today's Session
↗
January 20, 2025
Via
Benzinga
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
↗
January 17, 2025
Via
The Motley Fool
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
December 18, 2024
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.
Via
MarketBeat
Top 3 Health Care Stocks That May Dip This Month
↗
November 25, 2024
Via
Benzinga
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
↗
November 25, 2024
Via
The Motley Fool
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
↗
November 23, 2024
Via
The Motley Fool
MDGL: A Promising Play In The Weight Loss Drug Space
↗
November 22, 2024
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now...
Via
Talk Markets
Topics
Stocks / Equities
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
↗
November 10, 2024
There's a bright future ahead for this company.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
